Efeito antifúngico do extrato hidroalcoólico de Tropaeolum majus L. frente a dermatófitos causadores de Tinea pedis
DOI:
https://doi.org/10.35622/Palavras-chave:
atividade antifúngica, dermatófitos, extrato hidroalcoólico, tinea pedisResumo
As micoses superficiais são infecções cutâneas frequentes, e a tinea pedis está principalmente associada a dermatófitos como Trichophyton rubrum, T. mentagrophytes e Epidermophyton floccosum. Embora os antifúngicos sintéticos constituam o tratamento padrão, as recorrências, os efeitos adversos e a redução da sensibilidade fúngica têm motivado a avaliação de alternativas de origem vegetal. O objetivo deste estudo foi avaliar o efeito antifúngico do extrato hidroalcoólico das flores de Tropaeolum majus L. sobre o crescimento in vitro de T. rubrum, T. mentagrophytes e E. floccosum. Foi realizado um estudo experimental comparativo. Cinco extratos foram preparados por maceração utilizando gradientes de etanol de 65°, 70°, 80°, 85° e 90°. A atividade antifúngica foi determinada pelos métodos de difusão em disco (Kirby–Bauer) e difusão em poço em ágar, utilizando clotrimazol como controle positivo e água destilada como controle negativo. A resposta foi avaliada pelo diâmetro do halo de inibição e pela ausência de crescimento visível na área de difusão. Os resultados evidenciaram inibição do crescimento das três espécies em todos os extratos avaliados, com concordância entre ambas as técnicas e comportamento reprodutível nas réplicas. Em conjunto, os achados sustentam o potencial terapêutico de T. majus como fonte de compostos bioativos com possível aplicação no tratamento de micoses superficiais e respaldam sua consideração como alternativa fitoterápica complementar em cenários que buscam reduzir a dependência de antifúngicos sintéticos ou enfrentar problemas relacionados à resistência e acessibilidade.
Referências
Ward H, Parkes N, Smith C, Kluzek S, Pearson R. Consensus for the treatment of Tinea pedis: A systematic review of randomised controlled trials. J Fungi 2022;8:351. https://doi.org/10.3390/jof8040351.
Tausch I, Decroix J, Gwiezdzinski Z, Urbanowski S, Baran E, Ziarkiewicz M, Levy G, Del Palacio A. Short-term itraconazole versus terbinafine in the treatment of Tinea pedis or Tinea manus. Int J Dermatol. 1998;37(2):140–142. https://doi.org/10.1046/j.1365-4362.1998.00402.x
Thomas B, Falk J, Anderson GM. Topical management of tinea pedis. Can Fam Physician. 2021;67(1):30–34. https://doi.org/10.46747/cfp.670130
Aly R, Fisher G, Katz HI, Levine N, Lookingbill DP, Lowe N, et al. Ciclopirox gel in the treatment of patients with interdigital tinea pedis. Int J Dermatol 2003;42:29–35. https://doi.org/10.1046/j.1365-4362.42.s1.6.x.
Turkistani OA, Aljalfan AA, Albaqami MM, Bahayan AM. Epidemiology, evaluation and management of tinea pedis. Int J Community Med Public Health 2022;9:332–6. https://doi.org/10.18203/2394-6040.ijcmph20214832.
Sepahvand A, Behzadifar M, Raiesi O, Yarahmadi M. Prevalence of tinea pedis in military personnel: a systematic review and meta-analysis. BMC Public Health 2025;25:3116. https://doi.org/10.1186/s12889-025-24308-5.
Seebacher C, JP B, Mignon B. Updates on the epidemiology of dermatophyte infections. Mycopathologia 2008;166:335–52. https://doi.org/10.1007/s11046-008-9100-9.
Quiles I, García J. Antifúngicos de uso sistémico. Rev Iberoam Micol 2021;38:42–6. https://doi.org/10.1016/j.riam.2021.03.001.
De Keyser P, De Backer M, Massart DL, Westelinck KJ. Two-week oral treatment of Tinea pedis, comparing terbinafine (250 mg/day) with itraconazole (100 mg/day): a double-blind, multicentre study. Br J Dermatol. 1994;130(1):22–25. https://doi.org/10.1111/j.1365-2133.1994.tb06089.x
Biasi-Garbin RP, Demitto FO, Amaral RCR, Ferreira MRA, Soares LAL, Svidzinski TIE, Baeza LC, Yamada-Ogatta SF. Antifungal potential of plant species from Brazilian caatinga against dermatophytes. Rev Inst Med Trop Sao Paulo. 2016;58:18. https://doi.org/10.1590/S1678-9946201658018
Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2–15. https://doi.org/10.1111/j.1439-0507.2008.01606.x
Ward H, Parkes N, Smith C, Kluzek S, Pearson R. Consensus for the treatment of Tinea pedis: a systematic review of randomised controlled trials. J Fungi. 2022;8(4):351. https://doi.org/10.3390/jof8040351
Ali-Shtayeh MS, Abu Ghdeib SI. Antifungal activity of plant extracts against dermatophytes. Mycoses. 1999;42(11–12):665–672. https://doi.org/10.1046/j.1439-0507.1999.00499.x
Busquets-Carballo D, Galdós-Sánchez M, Fuente-Fernández N, al. et. Evaluación in vitro de la actividad antifúngica de extractos fluidos de Dichrostachys cinerea frente a Candida albicans. Arch Med Camaguey 2024;28. https://doi.org/10.57040/amc.2024.28.12.
Du L, Liu L, Zou S, Kou E, Wang B, Zhao H, et al. Interdigital antifungal socks for prevention and treatment of tinea pedis. J Infect Public Health 2024;17:102455. https://doi.org/10.1016/j.jiph.2024.05.043.
Aveiga I, Maldonado B. Prevalencia de micosis superficial en pacientes con lesiones sugestivas de dermatofitosis. Revista Minerva de Investigación Científica 2020;1:15–22. https://doi.org/10.5281/zenodo.8377954.
Arendrup MC, Kahlmeter G, Guinea J, Meletiadis J. How to perform antifungal susceptibility testing of microconidia-forming dermatophytes following the EUCAST method E.Def 11.0. Clin Microbiol Infect. 2021;27(1):55–60. https://doi.org/10.1016/j.cmi.2020.08.042
Leung AKC, Barankin B, Lam JM, Hon KL. Tinea pedis: an updated review. Drugs Context 2023;12:2021–3. https://doi.org/10.7573/dic.2023-5-1.
Aguilera B, Valcárcel R, Carauche S, Reyes F. Prevalencia y factores relacionados a onicomicosis y tinea pedis en futbolistas de Casanare, Colombia. Dermatología Cosmética, Médica y Quirúrgica 2021;19:327–32. https://doi.org/10.35366/103247.
Tertipi N, Sfyri E, Kefala V, Rallis E. Fungal skin infections in beach volleyball athletes in Greece. Hygiene 2024;4:458–68. https://doi.org/10.3390/hygiene4040034.
Favre B, Hofbauer B, Hildering K, NS R. Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay. J Clin Microbiol 2003;41:4817–9. https://doi.org/10.1128/JCM.41.10.4817-4819.2003.
Rotta I, Ziegelmann PK, Otuki MF. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis. JAMA Dermatol 2013;149:341–9. https://doi.org/10.1001/jamadermatol.2013.1721.
Molina A. Aspectos clínicos, diagnósticos y terapéuticos de las dermatofitosis. Enferm Infecc Microbiol Clin 2011;29:33–9. https://doi.org/10.1016/j.eimc.2010.10.002.
Aguirre-Vega R, Alvarado-Castillo G, Ramírez-Benítez M, al. et. Actividad antifúngica in vitro e in vivo de extractos de Azadirachta indica y Piper auritum contra Hemileia vastatrix. Rev Mex Fitopatol 2022;40:458–73. https://doi.org/10.18781/R.MEX.FIT.2203-4.
Nenoff P, Krüger C, Ginter-Hanselmayer G, HJ T. Mycology—an update: dermatophytosis: epidemiology, clinical aspects and resistance. J Dtsch Dermatol Ges 2014;12:188–209. https://doi.org/10.1111/ddg.12271.
Sinha SD, Rajamma A, Bandi MR, Sriramadasu SC, Sahu S, Kothiwala RK, Halder S, Sankerneni A, Panapakam M, Vemireddy VNR, Vattipalli R, Devireddy SR. Efficacy and safety of naftifine hydrochloride 2% gel in interdigital tinea pedis: a phase III randomised study. Clin Drug Investig. 2023;43:565–574. https://doi.org/10.1007/s40261-023-0128
Galili E, Taieb A, Shemer A, al. et. Epidemiology and trends of cutaneous fungal infections (2019–2022) in Israel: A single tertiary-center study. J Fungi (Basel) 2025;11:320. https://doi.org/10.3390/jof11040320.
Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol. 2010;28(2):197–201. https://doi.org/10.1016/j.clindermatol.2009.12.005
Reyes BA, Beutner KR, Cullen SI, Rosen T, Shupack JL, Weinstein MB. Butenafine, a fungicidal benzylamine derivative, used once daily for the treatment of interdigital tinea pedis. Br J Dermatol. 2002;146(Suppl 65):19–24. https://doi.org/10.1046/j.1365-4362.1998.00245.x
Alhammadi NA, Al-Jallal M, Al-Kaabi HA, Malibari WM. Prevalence and associated factors of tinea pedis in diabetic patients. Cureus 2023;15:e51210. https://doi.org/10.7759/cureus.51210.
Berman B, Ellis C, Leyden J, Lowe N, Savin R, Shupack J, et al. Efficacy of a 1-week, twice-daily regimen of terbinafine 1% cream in the treatment of interdigital tinea pedis. J Am Acad Dermatol 1992;26:956–60. https://doi.org/10.1016/0190-9622(92)70141-2.
Fernández-Torres B, Cabañes FJ, Carrillo-Muñoz AJ, Esteban A, Inza I, Abarca L, et al. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 2002;40:3999–4003. https://doi.org/10.1128/JCM.40.11.3999-4003.2002.
Guzmán-Pérez V, Bumke-Vogt C, Schreiner M, Mewis I, Borchert A, Pfeiffer AFH. Benzylglucosinolate derived isothiocyanate from Tropaeolum majus reduces gluconeogenic gene and protein expression in human cells. PLoS One 2016;11:e0162397–e0162397. https://doi.org/10.1371/journal.pone.0162397.
Santos DA, Hamdan JS. Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum. J Clin Microbiol. 2005;43(4):1917–1920. https://doi.org/10.1128/JCM.43.4.1917-1920.2005.
Ilkit M, Durdu M. Tinea pedis: the etiology and global epidemiology of a common fungal infection. Crit Rev Microbiol. 2015;41(3):374–388. https://doi.org/10.3109/1040841X.2013.856853
Da Silva Barros ME, de Assis Santos D, Hamdan JS. Evaluation of susceptibility of Trichophyton mentagrophytes and Trichophyton rubrum clinical isolates to antifungal drugs using a modified CLSI microdilution method (M38-A). J Med Microbiol. 2007;56(Pt 4):514–518. https://doi.org/10.1099/jmm.0.46542-0.
Foster KW, Ghannoum MA, Elewski BE. Epidemiologic surveillance of cutaneous fungal infection in the United States from 1999 to 2002. J Am Acad Dermatol. 2004;50(5):748–752. https://doi.org/10.1016/S0190-9622(03)02117-0.
Hernández-Sampieri R, Mendoza Torres CP. Metodología de la investigación: las rutas cuantitativa, cualitativa y mixta. McGraw-Hill Education; 2018.
Montgomery DC. Design and Analysis of Experiments. 10th ed. John Wiley & Sons; 2019.
